These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2085342)

  • 1. Successful development of recombinant DNA-derived pharmaceuticals.
    Werner RG; Pommer CH
    Arzneimittelforschung; 1990 Nov; 40(11):1274-83. PubMed ID: 2085342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of recombinant DNA produced pharmaceuticals by a combination of process validation and final product specifications.
    Jones AJ; O'Connor JV
    Dev Biol Stand; 1985; 59():175-80. PubMed ID: 4007276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three Rs potential in the development and quality control of pharmaceuticals.
    Hartung T
    ALTEX; 2001; 18 Suppl 1():3-13. PubMed ID: 11854852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meeting the regulatory requirements for pharmaceutical production of recombinant DNA derived products.
    Werner RG; Langlouis-Gau H
    Arzneimittelforschung; 1989 Jan; 39(1):108-11. PubMed ID: 2719737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specifications and quality control of a yeast-derived hepatitis B vaccine.
    Peetermans JH
    Postgrad Med J; 1987; 63 Suppl 2():97-100. PubMed ID: 3317364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective.
    Federsel HJ
    Acc Chem Res; 2009 May; 42(5):671-80. PubMed ID: 19338294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceuticals derived from genetically modified plants.
    Goldstein DA; Thomas JA
    QJM; 2004 Nov; 97(11):705-16. PubMed ID: 15496527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality assurance of products manufactured by recombinant DNA technology. Introduction and elements of a philosophy.
    van Noordwijk J
    Arzneimittelforschung; 1988 Jul; 38(7):943-7. PubMed ID: 3207439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene technology: chances for diagnosis and therapy.
    Werner RG
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):525-37. PubMed ID: 7885080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biocommodity Engineering.
    Lynd LR; Wyman CE; Gerngross TU
    Biotechnol Prog; 1999 Oct; 15(5):777-793. PubMed ID: 10514248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of therapeutic goods produced by recombinant DNA technology.
    Breschkin A
    Dev Biol Stand; 1987; 67():207-11. PubMed ID: 3475226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.